MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Chemotherapy

Survivin Expression as an Independent Predictor of Overall Survival in Malignant Peritoneal Mesothelioma

Oncology Letters 2020 June [Link] Guozun Zhang, Dong-Liang Yang, Guoqi Zheng, Yufei Liang Abstract Malignant peritoneal mesothelioma (MPeM) is an incurable cancer strongly associated with asbestos exposure and characterised by poor prognosis. The aim of the present study was to elucidate the prognostic and predictive value of CD146 and survivin expression in MPeM. Diagnostic biopsies […]

Comments Off on Survivin Expression as an Independent Predictor of Overall Survival in Malignant Peritoneal Mesothelioma

Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study.

Thoracic Cancer 2020 May 4 [Link] Trama A, Proto C, Signorelli D, Garassino MC, Lo Russo G, Ganzinelli M, Prelaj A, Mensi C, Gangemi M, Gennaro V, Chellini E, Caldarella A, Angelillo IF, Ascoli V, Pascucci C, Tagliabue G, Cusimano R, Bella F, Falcini F, Merler E, Masanotti G, Ziino A, Michiara M, Gola G, […]

Comments Off on Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study.

Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.

European Journal of Cancer 2020 April 4 [Link] Torricelli F, Saxena A, Nuamah R, Neat M, Harling L, Ng W, Spicer J, Ciarrocchi A, Bille A Abstract BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive tumour with poor prognosis. The aim of this study was to identify genetic mutations associated with poor or extended survival in […]

Comments Off on Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.

Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes.

Clinical Lung Cancer 2020 March 7 [Link] Lau B, Boyer M, Lee JH, Kao S Abstract INTRODUCTION: Studies of bevacizumab and pembrolizumab in the treatment of malignant pleural mesothelioma suggest anticancer efficacy; clinical trial populations are not reflective of real-world patients. We aimed to determine the proportion of real-world patients who would be eligible for […]

Comments Off on Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes.

Immunotherapy in Malignant Pleural Mesothelioma.

Frontiers in Oncology 2020 February 21 [Link] de Gooijer CJ, Borm FJ, Scherpereel A, Baas P Abstract The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. Immunotherapy did seem active in small phase II trials. In this review, we will highlight the most […]

Comments Off on Immunotherapy in Malignant Pleural Mesothelioma.

How I treat malignant pleural mesothelioma.

ESMO Open 2020 March [Link] Viscardi G, Di Liello R, Morgillo F Abstract Malignant pleural mesothelioma is a rare and aggressive malignancy mostly associated with occupational asbestos exposure. Prognosis is poor and only highly selected patients may benefit from aggressive surgical management, also as part of a multimodal approach. In advanced disease, the combination of […]

Comments Off on How I treat malignant pleural mesothelioma.

A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Lung Cancer 2020 February 12 [Link] Zucali PA, Perrino M, De Vincenzo F, Giordano L, Cordua N, D’Antonio F, Santoro A Abstract OBJECTIVES: Second-line chemotherapy is not a standard of care in patients with malignant pleural mesothelioma (MPM) that progresses after first-line treatment with cisplatin and pemetrexed. In pre-clinical models, the combination of gemcitabine (GEM) […]

Comments Off on A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.

Journal of Immunotherapy for Cancer 2020 February [Link] Hotta K, Fujimoto N Abstract Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both […]

Comments Off on Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).

Annals of Oncology 2020 January 16 [Link] Metaxas Y, Früh M, Eboulet EI, Grosso F, Pless M, Zucali PA, Ceresoli GL, Mark M, Schneider M, Maconi A, Perrino M, Biaggi-Rudolf C, Froesch P, Schmid S, Waibel C, Appenzeller C, Rauch D, von Moos R; Swiss Group for Clinical Cancer Research (SAKK). Abstract BACKGROUND: Systemic second- […]

Comments Off on Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).

Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.

Lung Cancer 2020 February 14 [Link] Bronte G, Delmonte A, Burgio MA, Verlicchi A, Puccetti M, Bravaccini S, Cravero P, Tumedei MM, Diano D, Rossi G, Ulivi P, Martinelli G, Crinò L Abstract OBJECTIVES: Treatment options for malignant pleural mesothelioma (MPM) are limited but some studies on immune checkpoint inhibitors (ICIs) in MPM have reported […]

Comments Off on Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.